Pulmonology Articles

Pulmonology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Holgate S et al. - Based on clinical trial data analysis, it is recommended that treatment response is evaluated by the physician after 16 weeks of therapy. Treatment should only be continued in responders, i.e. those judged by the physician to have achieved a marked improvement or complete asthma control. Omalizumab is generally well tolerated. Anaphylactic-like reactions are rare and less common than encountered with other biologics.

Related Articles

Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy
International Archives of Allergy and Immunology, 10/21/09    Relevance Score: 87%

Relationship between pretreatment specific IgE and the response to omalizumab therapy
Allergy, 11/12/09    Relevance Score: 85%

Effects of omalizumab on markers of inflammation in patients with allergic asthma
Allergy, 11/16/09    Relevance Score: 84%

“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
Respiratory Medicine, 10/13/09    Relevance Score: 84%

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma
Allergy and Asthma Proceedings, 10/12/09    Relevance Score: 83%

Today in Asthma/Atopy...keeping you current

Parental occupation is a risk factor for childhood wheeze and asthma
European Respiratory Journal , 12/04/09

Pulmonary Rehabilitation and Palliative Care
Seminars in Respiratory and Critical Care Medicine, 12/04/09

Adherence Feedback to Improve Asthma Outcomes Among Inner-City Children
Pediatrics, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address